Halozyme Therapeutics

Halozyme Therapeutics (HALO) is currently trading at $64.49. The stock has a 52-week range of $47.91 to $81.23 and a market capitalization of $7.64B.

Halozyme Therapeutics has a P/E ratio of 25.2 (forward P/E: 6.6), a dividend yield of none, and 1-year performance of +4.2%. 2 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.

There have been 50 insider transactions for HALO in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.

Halozyme Therapeutics (HALO) has returned +4.2% over the past 12 months. The stock traded between $47.91 and $81.23 during this period, and is currently at $64.49.

2 tracked hedge funds currently hold HALO in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.

Halozyme Therapeutics (HALO) has a market capitalization of $7.64B. The trailing P/E ratio is 25.2 and forward P/E is 6.6. The stock is classified in the Healthcare sector.

Halozyme Therapeutics reported revenue of $1.40B with net income of $316.89M and a profit margin of 0.23%. The stock has a beta of 1.03.

Halozyme Therapeutics (HALO) operates in the Healthcare sector. It is held by 2 tracked hedge funds. See the ownership table above for the complete list.